Biosimilar arthritis drug shows promise in small study
NCT ID NCT03885037
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a biosimilar version of the drug infliximab (made by Pfizer) in 77 people with rheumatoid arthritis. The goal was to see how safe and effective it is in real-world use. Participants received the drug by IV infusion, and researchers tracked side effects and disease activity over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- infliximab biosimilar (Pfizer)
- What this could lead to
- If successful, this could provide a more affordable treatment option for rheumatoid arthritis.
- What could go wrong
- This is a small, completed study without a control group, so results may not be generalizable. Biosimilars may have subtle differences in effectiveness or side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Local Country Office
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can group learning make biotherapy safer for arthritis patients?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?